Navigation Links
Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
Date:1/28/2009

rpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of pegloticase and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of pegloticase; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in ongoing or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today announced ... shares of its common stock at a price to ... to Tandem from this offering are expected to be ... other estimated offering expenses payable by Tandem. All of ...
(Date:2/26/2015)... BEND, Ind. , Feb. 26, 2015  Mobility ... announce an agreement with Bank of America (NYSE: ... consumers nationwide to receive financing of the revolutionary MV-1 ... vehicle, designed from the ground up to provide safe ... Approved applicants can use their loan to purchase a ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... Reportlinker.com announces that a new market research report ... Sanofi-Aventis: PharmaVitae Profile http://www.reportlinker.com/p0201760/Sanofi-Aventis-PharmaVitae-Profile.html ... examines the historical and forecast performance for Sanofi-Aventis ... company strategy, portfolio and pipeline analysis and assessment ...
... As technologies for fat removal become more advanced, physicians ... the body but also recycling the fat to further ... recent statistics from the American Society for Aesthetic Plastic ... two most popular invasive and non-invasive cosmetic procedures in ...
Cached Medicine Technology:Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 2Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 3Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 4Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 5Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 6Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 7The New Face of Body Contouring 2
(Date:2/28/2015)... (PRWEB) February 28, 2015 In recent years ... number of practicing physicians as a way for them to ... education regarding Cannabis as medicine. Since the FDA still lists ... few resources available to licensed physicians that can help ... patient. Dr. Deborah Malka in Santa Cruz, CA is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 With their ... Fitness has added an additional exercise to their already ... oblique exercise is most commonly known as, is often ... “Rope Pulls” are executed in a relatively safe manner ... and strength levels. The full description of “Rope Pulls” ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... 28, 2015 For those people who ... the Mesothelioma Applied Research Foundation (Meso Foundation) ... March 3, starting at 9:30 AM. , The live ... The broadcast can be accessed through any browser on ... , The Symposium is a unique event that covers ...
(Date:2/28/2015)... Pismo Beach, CA (PRWEB) February 28, 2015 ... the needs of Central Coast area residents, recently announced ... Whitening System. It’s a treatment option for new ... patients kick off 2015 with a bright, white smile, ... the discounted price of $299, marked down from the ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... Cardiva Medical, Inc. announced today that it has received ... for its latest technology, the Cardiva Catalyst III, which ... in the market. Built upon its predecessor, the ... which neutralizes heparin in the tissue adjacent to the ...
... 19 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... aesthetics, dermatology, environmental and nutraceutical products, today announced that ... Tuesday, June 2, 2009 at 4:30 PM Eastern Time. ... (U.S.) and 1-201-689-8471 (international). The call will also ...
... (www.meettheburns.com) targets first time athlete,s foot sufferers and ... Schering-Plough Corporation (NYSE: SGP ) ... antifungal spray for the treatment of athlete,s foot. ... spray and deodorant powder spray.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 ...
... profile "New Strategies for Optimizing CHO Performance" inside the BIO Process ... ... Fort Collins, CO (PRWEB) May 19, 2009 -- Amidst ... International Convention will be InVitria, a cell culture media supplement company ...
... patient with help from GI specialists, GI Monitor, an ... (IBD) Crohn,s and Ulcerative Colitis to track their symptoms ... N.J., May 19 WellApps, Inc. launched an iPhone ... Colitis provide accurate symptom data to their doctors for ...
... May 19 Regulatory processes differ across continents, ... pressing need to integrate the regulatory environment of ... regulations impact drug launches as less price controlled ... in regulated markets. The pharmaceutical industry, along with ...
Cached Medicine News:Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 2Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 3Health News:Nuvilex, Inc. Announces Monthly Investor Conference Call 2Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:InVitria to Present at BIO 2009 International Convention in Atlanta 2Health News:IBD Patient Launches iPhone Application to Help Doctors Treat Crohn's and Ulcerative Colitis 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4
... PC captures, displays, replays and analyzes ... proven to be effective in evaluating ... obstructive pulmonary disease.,It provides objective evidence ... , , Waveform and time-expanded ...
... Acoustic Cardioscan Viewer Phonocardiogram (PCG). The ... allows you to record, condition, display and ... stethoscope. The product acquires and displays ... to four sites, and allows user-selectable filtering ...
... The MULTIVIEW WORKSTATION enhances patient ... access, rapid assessment, decision support, and ... hospital. Part of the INFINITY Patient ... comprehensive patient information, including continuous, real-time ...
... The biograph 16 offers the ... disease diagnosis and treatment in ... delivers high-quality PET/CT whole body ... minutes. Our comprehensive suite of ...
Medicine Products: